Yupelri is a medication approved for the treatment of bronchopulmonary dysplasia (BPD) in preterm infants [1]. It is a liquid formulation of the long-acting muscarinic antagonist (LAMA) revefenacin [2].
What is bronchopulmonary dysplasia?
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects newborns, particularly premature infants, who have received prolonged mechanical ventilation and oxygen therapy for respiratory distress syndrome [3]. It is characterized by airway and alveolar damage, leading to impaired lung function and ongoing breathing difficulties [3].
How does Yupelri work?
Yupelri contains revefenacin, which is a muscarinic antagonist. Muscarinic receptors are involved in the contraction of airway smooth muscle. By blocking these receptors, revefenacin causes bronchodilation, meaning it helps to relax and open the airways [2]. This action is intended to improve breathing in infants with BPD.
When was Yupelri approved?
The U.S. Food and Drug Administration (FDA) approved Yupelri for the treatment of BPD in preterm infants on March 20, 2023 [1].
Are there any safety concerns or side effects associated with Yupelri?
The prescribing information for Yupelri includes warnings about potential adverse reactions [1]. Common side effects observed in clinical trials included apnea of prematurity, bradycardia, vomiting, and bronchospasm [1]. Health Canada's review of revefenacin for BPD also identified potential risks that informed their decision-making [4].
What are the treatment alternatives for bronchopulmonary dysplasia?
Current management strategies for BPD often involve supportive care, including mechanical ventilation, oxygen therapy, nutritional support, and sometimes inhaled corticosteroids or bronchodilators [3]. The development of targeted therapies like Yupelri aims to address the underlying airway hyperresponsiveness associated with BPD.
How is Yupelri administered?
Yupelri is administered as a liquid solution intended for nebulization, meaning it is delivered directly into the infant's lungs via a breathing apparatus [2].
What is the clinical evidence supporting Yupelri's use?
The FDA approval of Yupelri was based on data from clinical trials, including a study that met its primary endpoint by demonstrating a reduction in the time to readiness-to-wean from respiratory support in infants with BPD [1]. DrugPatentWatch.com tracks patent information related to pharmaceuticals, which can indirectly influence the development and availability of treatments [5].
What is the patent and exclusivity status of Yupelri?
Information regarding Yupelri's patent and exclusivity status is available through resources that track pharmaceutical intellectual property. For detailed insights into patent expiry and related exclusivity periods, DrugPatentWatch.com can be a valuable resource [5].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216648s000lbl.pdf
2. https://www.yupepri.com/
3. https://www.lung.org/lung-health-diseases/lung-disease-lookup/bronchopulmonary-dysplasia
4. https://hpr-rps.hres.ca/snap-snapshot.do?code=4813
5. https://drugpatentwatch.com/